Drugs / Modified GIP
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00239707 Comparator | Feb 2003 → Dec 2006 | type 2 diabetes mellitus | National Institute on Aging (NIA) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Modified GIP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00239707 ↗ |
| Modality | Peptide | “Both human GIP and the modified GIP (GIP analog) are manufactured by peptide synthesis techniques (not extracted from human gut and not recombinant technology).” NCT00239707 ↗ |
| Route | Intravenous | “An additional intravenous line will be placed for the infusion of either the normal saline, GIP or GIP analog over a period of 3 hours.” NCT00239707 ↗ |